Xcel Sues Par Pharma Unit Over ANDA For Diastat Generic
Xcel Pharmaceuticals has filed a lawsuit against Par Pharmaceuticals subsidiary Kali Laboratories over Kali's filing of an abbreviated new drug application (ANDA) for a generic version of the rectal gel Diastat....To view the full article, register now.
Already a subscriber? Click here to view full article